Cargando…
A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment
BACKGROUND AND OBJECTIVES: A photochemical treatment process (PCT) utilizing amotosalen and UVA light (INTERCEPT™ Blood System) has been developed for inactivation of viruses, bacteria, parasites and leucocytes that can contaminate blood components intended for transfusion. The objective of this stu...
Autores principales: | Knutson, F, Osselaer, J, Pierelli, L, Lozano, M, Cid, J, Tardivel, R, Garraud, O, Hervig, T, Domanovic, D, Cukjati, M, Gudmundson, S, Hjalmarsdottir, I B, Castrillo, A, Gonzalez, R, Brihante, D, Santos, M, Schlenke, P, Elliott, A, Lin, J-S, Tappe, D, Stassinopoulos, A, Green, J, Corash, L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690512/ https://www.ncbi.nlm.nih.gov/pubmed/25981525 http://dx.doi.org/10.1111/vox.12287 |
Ejemplares similares
-
Antibody profiles in COVID‐19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment
por: Bagri, Anil, et al.
Publicado: (2022) -
Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days
por: Infanti, Laura, et al.
Publicado: (2019) -
Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage
por: Cancelas, Jose A., et al.
Publicado: (2022) -
Preparation and Storage of Cryoprecipitate Derived from Amotosalen and UVA-Treated Apheresis Plasma and Assessment of In Vitro Quality Parameters
por: Kovacic Krizanic, Katarina, et al.
Publicado: (2022) -
Transfusion of pathogen‐reduced platelet components without leukoreduction
por: Sim, Joycelyn, et al.
Publicado: (2019)